AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $270,450 | +71.7% | 22,241 | +77.3% | 0.01% | +60.0% |
| Q2 2023 | $157,515 | +73162.8% | 12,541 | -35.3% | 0.01% | -28.6% |
| Q1 2023 | $215 | +481.1% | 19,380 | +550.3% | 0.01% | +250.0% |
| Q4 2022 | $37 | -100.0% | 2,980 | -96.6% | 0.00% | -86.7% |
| Q3 2022 | $921,000 | +79.2% | 88,209 | +84.6% | 0.02% | +25.0% |
| Q2 2022 | $514,000 | +49.9% | 47,790 | +31.7% | 0.01% | +300.0% |
| Q1 2022 | $343,000 | +40.0% | 36,282 | +70.8% | 0.00% | -25.0% |
| Q4 2021 | $245,000 | -44.4% | 21,248 | -54.0% | 0.00% | -63.6% |
| Q3 2021 | $441,000 | +123.9% | 46,173 | +126.6% | 0.01% | +120.0% |
| Q2 2021 | $197,000 | -31.8% | 20,380 | -30.5% | 0.01% | 0.0% |
| Q1 2021 | $289,000 | -50.5% | 29,323 | +15.9% | 0.01% | -72.2% |
| Q4 2020 | $584,000 | +382.6% | 25,308 | +195.6% | 0.02% | +1700.0% |
| Q3 2020 | $121,000 | -70.8% | 8,562 | -68.8% | 0.00% | -94.1% |
| Q2 2020 | $414,000 | +245.0% | 27,424 | +122.1% | 0.02% | +70.0% |
| Q4 2019 | $120,000 | +11900.0% | 12,346 | +12246.0% | 0.01% | – |
| Q3 2019 | $1,000 | -99.4% | 100 | -99.2% | 0.00% | -100.0% |
| Q3 2018 | $159,000 | +1035.7% | 13,192 | +1297.5% | 0.01% | +500.0% |
| Q4 2017 | $14,000 | -84.3% | 944 | -83.9% | 0.00% | -71.4% |
| Q3 2017 | $89,000 | – | 5,878 | +16694.3% | 0.01% | – |
| Q2 2017 | $0 | – | 35 | +29.6% | 0.00% | – |
| Q1 2017 | $0 | -100.0% | 27 | -98.8% | 0.00% | -100.0% |
| Q4 2016 | $12,000 | -86.4% | 2,340 | -74.2% | 0.00% | -92.9% |
| Q4 2015 | $88,000 | +57.1% | 9,064 | +77.7% | 0.01% | +100.0% |
| Q1 2015 | $56,000 | +133.3% | 5,102 | +27.6% | 0.01% | +133.3% |
| Q3 2014 | $24,000 | +200.0% | 4,000 | +73.4% | 0.00% | +200.0% |
| Q2 2014 | $8,000 | 0.0% | 2,307 | -38.3% | 0.00% | 0.0% |
| Q1 2014 | $8,000 | -20.0% | 3,737 | -10.9% | 0.00% | -50.0% |
| Q4 2013 | $10,000 | -28.6% | 4,193 | -31.8% | 0.00% | 0.0% |
| Q3 2013 | $14,000 | – | 6,151 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |